I reported previously (3rd Sep) on the US takeover of Israeli biotech Kite for $12 billion. The US FDA has now approved Kite’s Yescarta treatment for adults with relapsed or refractory large B-cell lymphoma. The treatment uses Israeli-developed CAR-T therapy from the patient’s own T-cells.

http://www.jns.org/news-briefs/2017/10/20/israeli-developed-breakthrough-cancer-drug-receives-fda-approval